INVESTING3 Biotech Stocks I Love for March (Celgene Is One of Them)By Bret JensenMar 1, 2018 10:30 PM EST
INVESTINGWhy I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second HalfBy Bret JensenJul 10, 2017 4:02 PM EDT
INVESTINGNo Easy Cure for What Ails Biotech Stocks Like Valeant, BiogenBy Bret JensenOct 22, 2015 2:28 PM EDT
INVESTINGBiotech Investors: Hillary's Attacks on Drug Price Gouging Will Go NowhereBy Bret JensenSep 22, 2015 1:00 PM EDT
REITs2 REITs That Should Do Well Even With Rising Interest RatesBy Bret JensenJun 9, 2015 6:10 AM EDT
INVESTINGFireEye, Gilead Sciences, and Aeropostale: Doug Kass' ViewsBy Bret JensenMay 25, 2015 1:01 AM EDT
INVESTINGNew York & Company and Micron Technologies: Doug Kass' ViewsBy Bret JensenMay 25, 2015 1:00 AM EDT
INVESTINGConsumer Stocks Didn’t Get Much of a Boost From Lower Gas PricesBy Bret JensenMay 15, 2015 6:20 AM EDT
INVESTINGStrong Dollar May Weigh on Apple and Gilead Earnings OutlooksBy Bret JensenApr 27, 2015 11:57 AM EDT
INVESTINGGeneral Motors Stock Is Driving -- Time to Take It for a SpinBy Bret JensenApr 24, 2015 6:01 AM EDT
INVESTINGNervous Investor? Stay Away From Tesla and Shake ShackBy Bret JensenMar 31, 2015 6:30 AM EDT
INVESTINGA Bargain 'Chip' for Value Investors in a Tumultuous MarketBy Bret JensenMar 30, 2015 10:27 AM EDT
TECHNOLOGYEven After Apple's Rally, There's No Reason to Sell the SharesBy Bret JensenFeb 13, 2015 10:41 AM EST
INVESTINGReal Money Pro's Bret Jensen: Scouring for Plays Amid the VolatilityBy Bret JensenOct 28, 2014 10:58 AM EDT
INVESTINGTwo Stocks Found Sifting Through the Wreckage of the Energy SectorBy Bret JensenOct 10, 2014 3:00 PM EDT
